Elanco Animal Health Incorporated Amortization of Intangible Assets
Elanco Animal Health Incorporated (ELAN) reported Amortization of Intangible Assets of $139.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-05
- Elanco Animal Health Incorporated amortization of intangible assets for the quarter ending 2026-06-30 was $139.00M, a 2.21% increase year-over-year.
- Elanco Animal Health Incorporated amortization of intangible assets for the quarter ending 2026-03-31 was $138.00M, a 7.81% increase year-over-year.
- Elanco Animal Health Incorporated amortization of intangible assets for the quarter ending 2025-12-31 was $139.00M, a 6.92% increase year-over-year.
- Elanco Animal Health Incorporated amortization of intangible assets for the quarter ending 2025-09-30 was $140.00M, a 5.26% increase year-over-year.
- Elanco Animal Health Incorporated amortization of intangible assets for fiscal 2025 was $543.00M, a 3.04% increase from fiscal 2024.
- Elanco Animal Health Incorporated amortization of intangible assets for fiscal 2024 was $527.00M, a 3.83% decline from fiscal 2023.
- Elanco Animal Health Incorporated amortization of intangible assets for fiscal 2023 was $548.00M, a 3.79% increase from fiscal 2022.
- Elanco Animal Health Incorporated amortization of intangible assets for fiscal 2022 was $528.00M, a 5.04% decline from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $139.00M 10-Q · filed 2026-08-05 | $277.00M 10-Q · filed 2026-08-05 | $416.00M derived: sum of 3 quarters · filed 2026-08-05 | $556.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $138.00M 10-Q · filed 2026-05-06 | $277.00M derived: sum of 2 quarters · filed 2026-05-06 | $417.00M derived: sum of 3 quarters · filed 2026-05-06 | $553.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $139.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $279.00M derived: sum of 2 quarters · filed 2026-02-24 | $415.00M derived: sum of 3 quarters · filed 2026-08-05 | $543.00M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $140.00M 10-Q · filed 2025-11-05 | $276.00M derived: sum of 2 quarters · filed 2026-08-05 | $404.00M 10-Q · filed 2025-11-05 | $534.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $136.00M 10-Q · filed 2026-08-05 | $264.00M 10-Q · filed 2026-08-05 | $394.00M derived: sum of 3 quarters · filed 2026-08-05 | $527.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $128.00M 10-Q · filed 2026-05-06 | $258.00M derived: sum of 2 quarters · filed 2026-05-06 | $391.00M derived: sum of 3 quarters · filed 2026-05-06 | $522.00M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $130.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $263.00M derived: sum of 2 quarters · filed 2026-02-24 | $394.00M derived: sum of 3 quarters · filed 2026-02-24 | $527.00M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $133.00M 10-Q · filed 2025-11-05 | $264.00M derived: sum of 2 quarters · filed 2025-11-05 | $397.00M 10-Q · filed 2025-11-05 | $535.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $131.00M 10-Q · filed 2025-08-07 | $264.00M 10-Q · filed 2025-08-07 | $402.00M derived: sum of 3 quarters · filed 2026-02-24 | $542.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $133.00M 10-Q · filed 2025-05-07 | $271.00M derived: sum of 2 quarters · filed 2026-02-24 | $411.00M derived: sum of 3 quarters · filed 2026-02-24 | $547.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $138.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $278.00M derived: sum of 2 quarters · filed 2026-02-24 | $414.00M derived: sum of 3 quarters · filed 2026-02-24 | $548.00M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $140.00M 10-Q · filed 2024-11-07 | $276.00M derived: sum of 2 quarters · filed 2024-11-07 | $410.00M 10-Q · filed 2024-11-07 | $540.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $136.00M 10-Q · filed 2024-08-08 | $270.00M 10-Q · filed 2024-08-08 | $400.00M derived: sum of 3 quarters · filed 2025-02-25 | $528.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $134.00M 10-Q · filed 2024-05-08 | $264.00M derived: sum of 2 quarters · filed 2025-02-25 | $392.00M derived: sum of 3 quarters · filed 2025-02-25 | $525.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $130.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $258.00M derived: sum of 2 quarters · filed 2025-02-25 | $391.00M derived: sum of 3 quarters · filed 2025-02-25 | $528.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $128.00M 10-Q · filed 2023-11-07 | $261.00M derived: sum of 2 quarters · filed 2023-11-07 | $398.00M 10-Q · filed 2023-11-07 | $537.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $133.00M 10-Q · filed 2023-08-07 | $270.00M 10-Q · filed 2023-08-07 | $409.00M derived: sum of 3 quarters · filed 2024-02-26 | $550.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $137.00M 10-Q · filed 2023-05-09 | $276.00M derived: sum of 2 quarters · filed 2024-02-26 | $417.00M derived: sum of 3 quarters · filed 2024-02-26 | $546.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $139.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $280.00M derived: sum of 2 quarters · filed 2024-02-26 | $409.00M derived: sum of 3 quarters · filed 2024-02-26 | $556.00M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $141.00M 10-Q · filed 2022-11-08 | $270.00M derived: sum of 2 quarters · filed 2022-11-08 | $417.00M 10-Q · filed 2022-11-08 | $580.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $129.00M 10-Q · filed 2022-08-08 | $276.00M 10-Q · filed 2022-08-08 | $439.00M derived: sum of 3 quarters · filed 2023-03-01 | $535.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $147.00M 10-Q · filed 2022-05-09 | $310.00M derived: sum of 2 quarters · filed 2023-03-01 | $406.00M derived: sum of 3 quarters · filed 2023-03-01 | $455.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $163.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $259.00M derived: sum of 2 quarters · filed 2023-03-01 | $308.00M derived: sum of 3 quarters · filed 2023-03-01 | $360.00M 10-K · filed 2023-03-01 | $359.90M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $96.00M 10-Q · filed 2021-11-05 | $95.60M 10-Q · filed 2020-11-06 | $145.00M derived: sum of 2 quarters · filed 2021-11-05 | $197.00M 10-Q · filed 2021-11-05 | $196.20M 10-Q · filed 2020-11-06 | $248.00M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $49.00M 10-Q · filed 2021-08-09 | $101.00M 10-Q · filed 2021-08-09 | $100.60M 10-Q · filed 2020-07-30 | $152.00M derived: sum of 3 quarters · filed 2022-02-28 | $202.70M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $52.00M 10-Q · filed 2021-05-07 | $51.60M 10-Q · filed 2020-05-07 | $103.00M derived: sum of 2 quarters · filed 2022-02-28 | $153.70M derived: sum of 3 quarters · filed 2022-02-28 | $203.00M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $51.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $101.70M derived: sum of 2 quarters · filed 2022-02-28 | $151.00M derived: sum of 3 quarters · filed 2022-02-28 | $200.00M 10-K · filed 2022-02-28 | $200.40M 10-K · filed 2020-02-28 | |||
| 2019-09-30 | $50.70M 10-Q · filed 2020-11-06 | $100.00M derived: sum of 2 quarters · filed 2020-11-06 | $149.00M 10-Q · filed 2020-11-06 | $199.10M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $49.30M 10-Q · filed 2020-07-30 | $98.30M 10-Q · filed 2020-07-30 | $148.40M derived: sum of 3 quarters · filed 2021-03-01 | $197.10M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $49.00M 10-Q · filed 2020-05-07 | $99.10M derived: sum of 2 quarters · filed 2021-03-01 | $147.80M derived: sum of 3 quarters · filed 2021-03-01 | $197.20M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $50.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $98.80M derived: sum of 2 quarters · filed 2021-03-01 | $148.20M derived: sum of 3 quarters · filed 2021-03-01 | $197.40M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $48.70M 10-Q · filed 2019-11-08 | $98.10M derived: sum of 2 quarters · filed 2019-11-08 | $147.30M 10-Q · filed 2019-11-08 | $207.50M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $49.40M 10-Q · filed 2019-08-13 | $98.60M 10-Q · filed 2019-08-13 | $158.80M derived: sum of 3 quarters · filed 2020-02-28 | $210.40M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-03-31 | $49.20M 10-Q · filed 2019-05-14 | $109.40M derived: sum of 2 quarters · filed 2020-02-28 | $161.00M derived: sum of 3 quarters · filed 2020-02-28 | |||||
| 2017-12-31 | $60.20M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $111.80M derived: sum of 2 quarters · filed 2020-02-28 | $221.20M 10-K · filed 2020-02-28 | |||||
| 2017-09-30 | $51.60M 10-Q · filed 2018-11-08 | $161.00M 10-Q · filed 2018-11-08 | ||||||
| 2016-12-31 | $170.70M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |